{
  "meta": {
    "timestamp": "2025-01-06T13:03:23.408696",
    "version": "1.0",
    "type": "search_analysis"
  },
  "companies": [
    {
      "company_name": "Compass Pathways PLC",
      "symbol": "CMPS",
      "analysis": {
        "historical": {
          "risk_score": 70,
          "key_risks": [
            "Regulatory and legal risks due to stringent FDA, DEA, and EMA oversight",
            "Clinical trial risks, including delays and potential failure to demonstrate efficacy or safety",
            "Competition and market risks from other companies developing similar therapies",
            "Financial and operational risks, including reliance on external funding and recent staff cuts"
          ],
          "controversies": [
            "Ethical concerns over patenting synthetic psilocybin",
            "Public perception challenges due to historical association of psychedelics with recreational use"
          ],
          "environmental_issues": [],
          "social_issues": [
            "Ethical concerns over commercializing naturally occurring compounds",
            "Public perception challenges affecting adoption and regulatory acceptance"
          ],
          "governance_issues": [
            "Recent staff cuts and financial pressures indicating potential governance challenges"
          ],
          "recommendation": "caution",
          "confidence_score": 80
        },
        "evidence": {
          "sources": [
            {
              "url": "",
              "title": "Compass Pathways: No Near-Term Fix For Struggling Psychedelic Therapy ...",
              "snippet": "The FDA is carefully evaluating therapies based on psilocybin, underscoring the regulatory challenges. This article updates the investment merits of Compass Pathways following my 01/2023 analysis ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Compass Pathways PLC Compass Pathways PLC regulatory challenges FDA EMA",
              "retrieved_at": "2025-01-06T20:02:53.908660+00:00",
              "published_date": null,
              "source_hash": "c0cf3d5144a0c3e77f11640ff50cb772"
            },
            {
              "url": "",
              "title": "Compass Pathways: Sector-Wide Reality Check Needed Post FDA Lykos MDMA ...",
              "snippet": "The FDA decision is not the end of the road for the psychedelics sector, but Compass Pathways and peers face serious challenges regarding regulatory approval, access to capital and commercialization.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Compass Pathways PLC Compass Pathways PLC regulatory challenges FDA EMA",
              "retrieved_at": "2025-01-06T20:02:53.908734+00:00",
              "published_date": null,
              "source_hash": "52f982cad1af8835eb70f03a2ece9e04"
            },
            {
              "url": "",
              "title": "COMPASS Pathways plc SEC 10-Q Report - TradingView",
              "snippet": "Regulatory Risks: The company's investigational COMP360 psilocybin treatment is subject to comprehensive regulation by the FDA, DEA, EMA, MHRA, and comparable foreign regulatory authorities. Failure to obtain regulatory approval in the U.S., Europe, or other jurisdictions will prevent the company from commercializing and marketing its treatment.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Compass Pathways PLC Compass Pathways PLC regulatory challenges FDA EMA",
              "retrieved_at": "2025-01-06T20:02:53.908749+00:00",
              "published_date": null,
              "source_hash": "99928e7a02d1a14f533b6fad7663c65c"
            },
            {
              "url": "",
              "title": "COMPASS Pathways: Overcoming Regulatory Hurdles with Promising Trial ...",
              "snippet": "Analyst Thomas Shrader of BTIG maintained a Buy rating on COMPASS Pathways (CMPS \u2013 Research Report), reducing the price target to $12.00. ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Compass Pathways PLC Compass Pathways PLC regulatory challenges FDA EMA",
              "retrieved_at": "2025-01-06T20:02:53.908761+00:00",
              "published_date": null,
              "source_hash": "77d7d1c0223c5b4786d0bb8a0da9884a"
            },
            {
              "url": "",
              "title": "Compass Pathways - Compass Pathways and Greenbrook TMS enter into three ...",
              "snippet": "Three-year research collaboration will investigate the development of scalable, commercial delivery models for COMP360 psilocybin treatment, if FDA-approved LONDON, Jan. 05, 2024 (GLOBE NEWSWIRE) - Compass Pathways plc (Nasdaq: CMPS) (\"Compass\"), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, and Greenbrook TMS Inc. (NASDAQ ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Compass Pathways PLC Compass Pathways PLC clinical trial failures risks",
              "retrieved_at": "2025-01-06T20:03:01.996181+00:00",
              "published_date": null,
              "source_hash": "1f06d228ccb5c097b58118a6273cf39f"
            },
            {
              "url": "",
              "title": "Compass Pathways' Losses Widen in Q3 - The Motley Fool",
              "snippet": "Compass Pathways (CMPS 7.23%), a pioneer in psychedelic therapies, released its third-quarter results on Oct. 31. The report featured a slightly narrower-than-expected net loss of $0.56 per share ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Compass Pathways PLC Compass Pathways PLC regulatory challenges FDA EMA",
              "retrieved_at": "2025-01-06T20:02:53.908788+00:00",
              "published_date": null,
              "source_hash": "f7e578f2a704a9a5eeccd1d733409fb8"
            },
            {
              "url": "",
              "title": "COMPASS Pathways plc (CMPS): SWOT Analysis [10-2024 Updated] - dcf-fm",
              "snippet": "In an ever-evolving landscape of mental health treatment, COMPASS Pathways plc (CMPS) stands at the forefront with its groundbreaking approach to psychedelic therapies, particularly through its innovative product, COMP360 psilocybin.As of 2024, the company boasts a robust financial position with $207 million in cash reserves and advanced clinical trials aimed at addressing treatment-resistant ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Compass Pathways PLC Compass Pathways PLC regulatory challenges FDA EMA",
              "retrieved_at": "2025-01-06T20:02:53.908800+00:00",
              "published_date": null,
              "source_hash": "0572445554540a776d2d4e9409a7a7db"
            },
            {
              "url": "",
              "title": "Compass Pathways PLC | Reuters",
              "snippet": "The latest international Compass Pathways PLC news and views from Reuters - one of the world's largest news agencies ... plans to file for regulatory approval for the party drug MDMA as a ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Compass Pathways PLC Compass Pathways PLC regulatory challenges FDA EMA",
              "retrieved_at": "2025-01-06T20:02:53.908811+00:00",
              "published_date": null,
              "source_hash": "869adcfed137f102806e2a0bd4d55fed"
            },
            {
              "url": "",
              "title": "Compass Pathways PLC (CMPS) Q3 2024 Earnings Call Highlights ...",
              "snippet": "Despite workforce reductions and trial delays, Compass Pathways PLC (CMPS) maintains a strong cash position and focuses on commercializing COMP360 for treatment-resistant depression.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Compass Pathways PLC Compass Pathways PLC regulatory challenges FDA EMA",
              "retrieved_at": "2025-01-06T20:02:53.908820+00:00",
              "published_date": null,
              "source_hash": "8db472dd12696a04115bb2961219e638"
            },
            {
              "url": "",
              "title": "Compass Pathways and Greenbrook TMS enter into three-year ... - Nasdaq",
              "snippet": "LONDON, Jan. 05, 2024-- Compass Pathways plc, a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, and Greenbrook TMS Inc., a leading ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Compass Pathways PLC Compass Pathways PLC regulatory challenges FDA EMA",
              "retrieved_at": "2025-01-06T20:02:53.908830+00:00",
              "published_date": null,
              "source_hash": "50bb5d9d8e44e2b8b9009c479ed40784"
            },
            {
              "url": "",
              "title": "Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI)",
              "snippet": "LONDON--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology ... the lives of those who are living with mental health challenges and who are not helped by existing standards ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Compass Pathways PLC Compass Pathways PLC regulatory challenges FDA EMA",
              "retrieved_at": "2025-01-06T20:02:56.469576+00:00",
              "published_date": "2024-12-18T06:30:00+00:00",
              "source_hash": "1897b8443e0c53013f7cf994fcccde46"
            },
            {
              "url": "",
              "title": "COMPASS Pathways plc (CMPS)",
              "snippet": "LONDON, December 18, 2024--Compass Pathways plc (Nasdaq: CMPS), a biotechnology ... made ahead of pivotal study results, potential regulatory approval and subsequent commercialization of ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Compass Pathways PLC Compass Pathways PLC regulatory challenges FDA EMA",
              "retrieved_at": "2025-01-06T20:02:56.469682+00:00",
              "published_date": "2025-01-03T21:00:00+00:00",
              "source_hash": "59796ad216f278ffb9cdd50730f5cfaa"
            },
            {
              "url": "",
              "title": "Compass Pathways to Participate in December Investor Conferences",
              "snippet": "LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology ... lives of those who are living with mental health challenges and who are not helped by existing ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Compass Pathways PLC Compass Pathways PLC regulatory challenges FDA EMA",
              "retrieved_at": "2025-01-06T20:02:56.469711+00:00",
              "published_date": "2024-11-25T16:00:00+00:00",
              "source_hash": "2dc1d0fab7be57de7a7dcae1d3afcbb8"
            },
            {
              "url": "",
              "title": "Barclays PLC Cuts Stock Holdings in COMPASS Pathways plc (NASDAQ:CMPS)",
              "snippet": "COMPASS Pathways plc has a 1 year low of $3.86 and a 1 year high of $12.75. COMPASS Pathways ( NASDAQ:CMPS - Get Free Report ) last released its quarterly earnings results on Thursday, October 31st.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Compass Pathways PLC Compass Pathways PLC regulatory challenges FDA EMA",
              "retrieved_at": "2025-01-06T20:02:56.469734+00:00",
              "published_date": "2024-12-25T00:00:00+00:00",
              "source_hash": "edf41aead4469e7c7d9dcc18845c37c3"
            },
            {
              "url": "",
              "title": "Compass Pathways' SWOT analysis: psilocybin stock faces trials and trillion-dollar potential",
              "snippet": "Recent reports indicate that the company has faced challenges ... regulatory submission for COMP006, the company's investigational new drug application. The market for treatment-resistant depression represents a substantial opportunity for Compass Pathways.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Compass Pathways PLC Compass Pathways PLC regulatory challenges FDA EMA",
              "retrieved_at": "2025-01-06T20:02:56.469757+00:00",
              "published_date": "2024-12-18T06:40:00+00:00",
              "source_hash": "dd6d7554dca2ad09d9902ae0eb8f15c8"
            },
            {
              "url": "",
              "title": "Appeal Board Upholds Compass Pathways' Patent on Synthetic Psilocybin ...",
              "snippet": "A psychedelics company recently scored a major win after the Patent Trial and Appeal Board (PTAB) upheld a novel psychedelic patent that was under challenge. Compass Pathways PLC (NASDAQ: CMPS), a mental healthcare company based in the United Kingdom, synthesized and patented a type of psilocybin called Comp 360. In late 2021, a nonprofit called Freedom to Operate issued a legal challenge ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Compass Pathways PLC Compass Pathways PLC psilocybin patent controversy",
              "retrieved_at": "2025-01-06T20:02:57.799222+00:00",
              "published_date": null,
              "source_hash": "6706895f479a9b9536848439ac167a65"
            },
            {
              "url": "",
              "title": "Compass Pathways Plc Patent: Treating Anxiety Disorder with Crystalline ...",
              "snippet": "Compass Pathways's grant share as of February 2024 was 19%. Grant share is based on the ratio of number of grants to total number of patents. Patent granted for treating anxiety disorder with crystalline psilocybin. Source: United States Patent and Trademark Office (USPTO). Credit: Compass Pathways Plc",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Compass Pathways PLC Compass Pathways PLC psilocybin patent controversy",
              "retrieved_at": "2025-01-06T20:02:57.799343+00:00",
              "published_date": null,
              "source_hash": "4b8137feb4086f761fef06c4b25375a3"
            },
            {
              "url": "",
              "title": "Compass Pathways | Biotechnology Company",
              "snippet": "Compass Pathways is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are studying investigational psilocybin treatment in treatment-resistant depression , post-traumatic stress disorder and anorexia nervosa .",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Compass Pathways PLC Compass Pathways PLC psilocybin patent controversy",
              "retrieved_at": "2025-01-06T20:02:57.799374+00:00",
              "published_date": null,
              "source_hash": "24f15dc8e69f5fe04ed4733a57a27107"
            },
            {
              "url": "",
              "title": "New Filing Challenges Compass Pathways' Infamous Patent on ... - VICE",
              "snippet": "Psilocybin is the active compound in magic mushrooms, and whether it can be intellectual property has been the subject of debate, especially since the mental health company Compass Pathways was ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Compass Pathways PLC Compass Pathways PLC psilocybin patent controversy",
              "retrieved_at": "2025-01-06T20:02:57.799400+00:00",
              "published_date": null,
              "source_hash": "407eb5b69356cb90864845ae9da5dc59"
            },
            {
              "url": "",
              "title": "COMP360 psilocybin treatment in TRD - Compass Pathways",
              "snippet": "About the phase 2b trial. Our randomised controlled phase 2b study of investigational psilocybin treatment in treatment-resistant depression is the largest psilocybin treatment clinical trial ever conducted, with 233 patients across 22 sites in 10 countries across Europe and North America. This trial assessed the safety and efficacy of COMP360 psilocybin treatment in three doses: 1mg, 10mg, 25mg.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Compass Pathways PLC Compass Pathways PLC psilocybin patent controversy",
              "retrieved_at": "2025-01-06T20:02:57.799423+00:00",
              "published_date": null,
              "source_hash": "27e4660e330797e5ec08da7c613bc341"
            },
            {
              "url": "",
              "title": "Compass has the most advanced psychedelic drug in trials \u2014 but it needs ...",
              "snippet": "Since the company's launch in 2016, UK-based Compass Pathways has led the psychedelic boom in biotech. With a therapy that has advanced further than any other in the field while showing positive results in some of the largest clinical trials of a psychedelic drug to date, Compass has helped demonstrate how a biotech built on a \"party drug\" can succeed in the world of traditional pharma.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Compass Pathways PLC Compass Pathways PLC psilocybin patent controversy",
              "retrieved_at": "2025-01-06T20:02:57.799448+00:00",
              "published_date": null,
              "source_hash": "9a994ebc20fb54858c3c51f29bd997c3"
            },
            {
              "url": "",
              "title": "Compass Psychological Support Model for COMP360 Psilocybin Treatment of ...",
              "snippet": "COMP360 psilocybin treatment consists of the administration of the investigational drug COMP360, a Compass Pathfinder Ltd (Compass) proprietary formulation of synthetic psilocybin, with psychological support. ... Dr. Goodwin, and Dr. Koelpin are current or past employees of subsidiaries of Compass Pathways plc and own shares, share options, and ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Compass Pathways PLC Compass Pathways PLC psilocybin patent controversy",
              "retrieved_at": "2025-01-06T20:02:57.799488+00:00",
              "published_date": null,
              "source_hash": "5944e0d7bbd9ed29f0a8b3c4fd325d51"
            },
            {
              "url": "",
              "title": "COMPASS Pathways is granted new US patent for crystalline psilocybin",
              "snippet": "This is COMPASS's first patent with claims covering its Form A hydrate psilocybin. ... 19 October 2021 COMPASS Pathways plc (Nasdaq: CMPS) (\"COMPASS\"), a mental health care company dedicated ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Compass Pathways PLC Compass Pathways PLC psilocybin patent controversy",
              "retrieved_at": "2025-01-06T20:02:57.799498+00:00",
              "published_date": null,
              "source_hash": "5baeece1f223b24556fd8777ad34710f"
            },
            {
              "url": "",
              "title": "COMPASS Pathways granted fifth US patent for crystalline psilocybin",
              "snippet": "London, UK - 23 November 2021 COMPASS Pathways plc (Nasdaq: CMPS) (\"COMPASS\"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Compass Pathways PLC Compass Pathways PLC psilocybin patent controversy",
              "retrieved_at": "2025-01-06T20:02:57.799508+00:00",
              "published_date": null,
              "source_hash": "6016186261a889afcdbb29455e65ede2"
            },
            {
              "url": "",
              "title": "Compass points to positive psilocybin trial, but shares fall",
              "snippet": "Compass Pathways has reported that its drug for treatment-resistant depression (TRD) based on magic mushroom ingredient psilocybin was effective in a phase 2b trial, although shares in the company ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Compass Pathways PLC Compass Pathways PLC psilocybin patent controversy",
              "retrieved_at": "2025-01-06T20:03:00.456183+00:00",
              "published_date": "2024-12-28T23:59:00+00:00",
              "source_hash": "93d29a2cb76bd9b0e84894339a08da8b"
            },
            {
              "url": "",
              "title": "Mental Health Treatment: Compass Pathways And Greenbrook TMS Join Forces For Psilocybin Therapy Research",
              "snippet": "Biotechnology company Compass Pathways plc (NASDAQ: CMPS ... agreement to explore delivery models for investigational COMP360 psilocybin treatment. The parties will research and investigate ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Compass Pathways PLC Compass Pathways PLC psilocybin patent controversy",
              "retrieved_at": "2025-01-06T20:03:00.456287+00:00",
              "published_date": "2024-01-05T16:50:00+00:00",
              "source_hash": "cc9d4e0454478a3f7ffecd9ec8617b02"
            },
            {
              "url": "",
              "title": "Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI)",
              "snippet": "LONDON--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology ... We are pioneering the development of a new model of psilocybin treatment, in which our proprietary formulation ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Compass Pathways PLC Compass Pathways PLC psilocybin patent controversy",
              "retrieved_at": "2025-01-06T20:03:00.456316+00:00",
              "published_date": "2024-12-18T06:30:00+00:00",
              "source_hash": "50dac3869ef710d3ddf73685d93781d7"
            },
            {
              "url": "",
              "title": "COMPASS Pathways plc (NASDAQ:CMPS) Given Consensus Rating of \"Buy\" by Brokerages",
              "snippet": "COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Compass Pathways PLC Compass Pathways PLC clinical trial failures risks",
              "retrieved_at": "2025-01-06T20:03:04.554283+00:00",
              "published_date": "2024-12-25T00:00:00+00:00",
              "source_hash": "d87bd5720b888e5f799d1d6c67be9546"
            },
            {
              "url": "",
              "title": "Compass points to job cuts as it defers trial readouts",
              "snippet": "Shares in psychedelic drug developer Compass Pathways are sliding today after ... will shift the data readout for phase 3 trials of the psilocybin-based COMP360 therapy until after the 26-week ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Compass Pathways PLC Compass Pathways PLC psilocybin patent controversy",
              "retrieved_at": "2025-01-06T20:03:00.456362+00:00",
              "published_date": "2025-01-02T00:00:00+00:00",
              "source_hash": "502178faecb4a58fee5713016adb7bbe"
            },
            {
              "url": "",
              "title": "Psychedelics haven't fulfilled clinical expectations, but new trial ...",
              "snippet": "In the wake of the Lykos decision, Compass Pathways, which has the most clinically-advanced psilocybin treatment for depression, recently delayed its timeline to report phase 3 results to ensure the trial can withstand the high level of scrutiny related to trial blinding.The company also announced plans to axe nearly a third of its staff.. The setbacks are a reminder that industry hype doesn ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Compass Pathways PLC Compass Pathways PLC clinical trial failures risks",
              "retrieved_at": "2025-01-06T20:03:01.995971+00:00",
              "published_date": null,
              "source_hash": "7f078765d77aaecf1ba8bad1ace07080"
            },
            {
              "url": "",
              "title": "Were Compass Pathways' Clinical Trial Results Really That Bad?",
              "snippet": "Brian Orelli: Compass Pathways -- ticker there is CMPS -- released data last week for its COMP360 psilocybin. That's a drug that comes out of the magic mushrooms; it's a treatment for depression ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Compass Pathways PLC Compass Pathways PLC clinical trial failures risks",
              "retrieved_at": "2025-01-06T20:03:01.996092+00:00",
              "published_date": null,
              "source_hash": "b56968d0c0001ae81fea211df5ec706f"
            },
            {
              "url": "",
              "title": "Compass Pathways: Phase 3 Trial Delay - Seeking Alpha",
              "snippet": "Introduction. COMPASS Pathways plc (NASDAQ:CMPS) released 3Q24 results on October 31, 2024.The result was taken very negatively by the market, triggering a sell-off to $4.75, down -23% on the day ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Compass Pathways PLC Compass Pathways PLC clinical trial failures risks",
              "retrieved_at": "2025-01-06T20:03:01.996109+00:00",
              "published_date": null,
              "source_hash": "2db3e789ae2f0272025354a78c169f46"
            },
            {
              "url": "",
              "title": "Compass Pathways' Costs Rise in Q2 as Clinical Trials Advance",
              "snippet": "Compass Pathways (CMPS 14.04%), an innovator the mental health space, released its second quarter report on July 30. The headline figure was a wider loss than anticipated, as it reported a net ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Compass Pathways PLC Compass Pathways PLC clinical trial failures risks",
              "retrieved_at": "2025-01-06T20:03:01.996120+00:00",
              "published_date": null,
              "source_hash": "add2cd74610b05b42aec76ef40184a12"
            },
            {
              "url": "",
              "title": "COMPASS Pathways plc SEC 10-Q Report - TradingView",
              "snippet": "COMPASS Pathways has undertaken several strategic initiatives to support its long-term growth and financial stability: Advancing Clinical Trials: The company is advancing its late-stage clinical trials for COMP360 psilocybin treatment, particularly focusing on treatment-resistant depression (TRD). This includes a Phase 3 program composed of two ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Compass Pathways PLC Compass Pathways PLC clinical trial failures risks",
              "retrieved_at": "2025-01-06T20:03:01.996130+00:00",
              "published_date": null,
              "source_hash": "aa07c9f1dc98f5fc5f2bc795a3e98355"
            },
            {
              "url": "",
              "title": "Compass Pathways: No Near-Term Fix For Struggling Psychedelic Therapy ...",
              "snippet": "Compass Pathways is advancing pivotal trials to test psilocybin's impact on treatment-resistant depression. Developing therapies based on controlled substances involves unique risks, which Compass ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Compass Pathways PLC Compass Pathways PLC clinical trial failures risks",
              "retrieved_at": "2025-01-06T20:03:01.996142+00:00",
              "published_date": null,
              "source_hash": "b69dce725b57ad02e584f366f7bf3cd3"
            },
            {
              "url": "",
              "title": "Compass Pathways and Greenbrook TMS enter into three-year research ...",
              "snippet": "These risks, uncertainties, and other factors include, among others: clinical development is lengthy and outcomes are uncertain, and therefore Compass's clinical trials may be delayed or ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Compass Pathways PLC Compass Pathways PLC clinical trial failures risks",
              "retrieved_at": "2025-01-06T20:03:01.996152+00:00",
              "published_date": null,
              "source_hash": "010dc36ddeff368890c6633ec5b7a92a"
            },
            {
              "url": "",
              "title": "Compass Pathways and Journey Clinical establish research collaboration ...",
              "snippet": "These risks, uncertainties, and other factors include, among others: clinical development is lengthy and outcomes are uncertain, and therefore Compass's clinical trials may be delayed or ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Compass Pathways PLC Compass Pathways PLC clinical trial failures risks",
              "retrieved_at": "2025-01-06T20:03:01.996161+00:00",
              "published_date": null,
              "source_hash": "7ef5a71f36dc029c051b33ad6bf60d6c"
            },
            {
              "url": "",
              "title": "COMPASS Pathways plc Announces Business Updates",
              "snippet": "Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in the development of psilocybin treatment, in which its investigational COMP360 psilocybin is administered in conjunction with psychological support, COMP360 ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Compass Pathways PLC Compass Pathways PLC clinical trial failures risks",
              "retrieved_at": "2025-01-06T20:03:01.996170+00:00",
              "published_date": null,
              "source_hash": "257d4807ed24fe99274943069d866205"
            },
            {
              "url": "",
              "title": "Compass points to job cuts as it defers trial readouts",
              "snippet": "Shares in psychedelic drug developer Compass Pathways are sliding today after ... that it will shift the data readout for phase 3 trials of the psilocybin-based COMP360 therapy until after the ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Compass Pathways PLC Compass Pathways PLC clinical trial failures risks",
              "retrieved_at": "2025-01-06T20:03:04.554176+00:00",
              "published_date": "2025-01-02T00:00:00+00:00",
              "source_hash": "ca37495bb1b085dec5484e7722fa960d"
            },
            {
              "url": "",
              "title": "Mental Health Treatment: Compass Pathways And Greenbrook TMS Join Forces For Psilocybin Therapy Research",
              "snippet": "Biotechnology company Compass Pathways plc (NASDAQ ... a phase 3 clinical program of COMP360 in TRD and intends to apply for FDA approval upon completion of clinical trials.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Compass Pathways PLC Compass Pathways PLC clinical trial failures risks",
              "retrieved_at": "2025-01-06T20:03:04.554315+00:00",
              "published_date": "2024-01-05T16:50:00+00:00",
              "source_hash": "fc6357eaa653080f9698162183e61eca"
            },
            {
              "url": "",
              "title": "Compass plans $100m IPO to fund magic mushroom depression drug",
              "snippet": "UK biotech Compass Pathways is ... but after a troubled clinical development with mixed results from clinical trials and question marks over side effects, with increased risks for dissociation ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Compass Pathways PLC Compass Pathways PLC clinical trial failures risks",
              "retrieved_at": "2025-01-06T20:03:04.554339+00:00",
              "published_date": "2025-01-03T00:00:00+00:00",
              "source_hash": "0e8f85978cf55ffd43775994f804da58"
            },
            {
              "url": "",
              "title": "Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI)",
              "snippet": "LONDON--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq ... such reconstitution; clinical development is lengthy and outcomes are uncertain, and therefore our clinical trials may be delayed or ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Compass Pathways PLC Compass Pathways PLC clinical trial failures risks",
              "retrieved_at": "2025-01-06T20:03:04.554362+00:00",
              "published_date": "2024-12-18T06:30:00+00:00",
              "source_hash": "04d2edd80e8df20dc44d4e6be5aa10f7"
            }
          ],
          "queries": [
            {
              "category": "financial_legal",
              "query": "Compass Pathways PLC regulatory challenges FDA EMA",
              "rationale": "Investigate potential legal and regulatory hurdles in obtaining approvals for COMP360",
              "priority": 1
            },
            {
              "category": "ethical_social",
              "query": "Compass Pathways PLC psilocybin patent controversy",
              "rationale": "Explore ethical concerns related to patenting naturally occurring psychedelic compounds",
              "priority": 2
            },
            {
              "category": "financial_legal",
              "query": "Compass Pathways PLC clinical trial failures risks",
              "rationale": "Assess risks associated with potential failures in ongoing Phase 3 trials for COMP360",
              "priority": 1
            }
          ]
        },
        "categorization": {
          "product_issues": [],
          "conduct_issues": [],
          "tags": [],
          "patterns": {}
        }
      },
      "metadata": {
        "analysis_timestamp": "2025-01-06T13:03:23.408703",
        "data_confidence": 80,
        "pattern_confidence": null
      }
    }
  ]
}